注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
信達生物製藥是一家主要從事生物製藥的投資控股公司。該公司及其子公司從事抗體及蛋白質醫藥產品的研發、藥品的銷售及分銷,以及提供諮詢及研發服務。該公司的主要產品為達伯舒(信迪利單抗注射液),用於治療復發或難治性經典霍奇金淋巴瘤。該公司的產品還包括阿達木單抗生物類似藥IBI-303,用於治療類風濕性關節炎、強直性脊柱炎及銀屑病。貝伐珠單抗生物類似藥IBI-305,用於治療轉移性結直腸癌及晚期、轉移性或複發性非小細胞肺癌(NSCLC)。利妥昔單抗生物類似藥IBI-301,用於治療非霍奇金淋巴瘤及慢性淋巴細胞白血病。該公司的產品應用於腫瘤、代謝、免疫學及眼底病等領域。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
De-Chao Yu | 58 | 2011 | Co-Founder, Chairman & CEO |
Vivian Zhang | - | 2019 | Chief People Officer, GM & Executive Director |
Hao Xi Ede | 65 | 2024 | Executive Director & Fund Managing Partner |
Qian Zhang | 37 | 2024 | Executive Director |
Charles Leland Cooney | 80 | 2015 | Member of CMC Strategic Advisory Board & Independent Non-Executive Director |
Shuyun Chen | 50 | 2024 | Independent Non-Executive Director |
I-Yin Hsu | 49 | 2018 | Independent Non-Executive Director |
Kai-Xian Chen | 78 | 2018 | Independent Non-Executive Director |
Lewis L. Lanier | - | 2021 | Member of Scientific Advisory Board |
Lawrence Fong | - | 2021 | Member of Scientific Advisory Board |
David LaPre | 72 | - | Member of CMC Strategic Advisory Board |
Erwin Vanhaecke | - | - | Member of CMC Strategic Advisory Board |
Chiang Syin | 68 | - | Member of CMC Strategic Advisory Board |
Shun Lu | 59 | 2024 | Independent Non-Executive Director |
Carlos Garcia-Echeverria | 59 | 2021 | Member of Scientific Advisory Board |
Gary J. Zieziula | 69 | 2022 | Independent Non-Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核